BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize targeted heat therapy
to treat cancer, today announced growing interest in hyperthermia at the
2012 international conference of the American Society for Radiation
Oncology (ASTRO). ASTRO is the largest radiation oncology society in the
world, and the annual conference is the premier worldwide scientific
meeting in radiation oncology. The theme of the 2012 meeting was
“Advancing Patient Care Through Innovation.”

BSD offers technologically innovative products that provide targeted
heat therapy for the treatment of cancer. Hyperthermia has been shown to
be the most potent radiosensitizing agent known to date and has
demonstrated the ability to increase the effectiveness of radiation and
many chemotherapeutic agents for certain tumors.

“Exhibiting at ASTRO allowed BSD to showcase the Company’s hyperthermia
technology to interested physicians and distributors throughout the
world,” stated Harold R. Wolcott, President of BSD Medical. “We were
pleased with the increased level of interest in hyperthermia shown by
both the U.S. and the international medical community and distributors.”

About ASTRO

ASTRO is the largest radiation oncology organization of its kind and has
more than 10,000 members. Their members include radiation oncologists,
radiation oncology nurses, medical physicists, radiation therapists,
dosimetrists and biologists, the medical professionals that are part of
the medical teams that treat more than 1 million cancer patients each
year. ASTRO is committed to excellence in patient care through a
team-based approach to treatment.

About the BSD Hyperthermia Systems

The BSD-500 Hyperthermia System (BSD-500) is used to deliver
therapeutic, targeted heat therapy (hyperthermia) using either
non-invasive (external) or interstitial (internal) applicators. The
BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market
approval (PMA), which is the standard FDA approval required to market
Class III medical devices in the United States, for the use of
hyperthermia alone or in conjunction with radiation therapy for the
treatment of certain tumors. Clinical studies have shown that
hyperthermia delivered using the BSD-500 can significantly increase the
effectiveness of radiation therapy without a significant increase in
toxicity for certain tumors.

The BSD-2000 – developed and patented exclusively by BSD – delivers
localized therapeutic heating (hyperthermia) by applying radiofrequency
(RF) energy. The BSD-2000 creates a central focusing of energy that can
be electronically focused to target the shape, size and location of the
tumor, thus providing dynamic control of the heating delivered to the
tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE)
marketing approval from the U.S. Food and Drug Administration (FDA) for
use in conjunction with radiation therapy for the treatment of cervical
cancer patients who are ineligible for chemotherapy. The BSD-2000 also
has CE (Conformité Européenne) Marking approval for the commercial sale
in Europe. CE Marking approval is also recognized in many countries
outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services
systems to treat cancer and benign diseases using heat therapy delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product
lines include both hyperthermia and ablation treatment systems. BSD’s
hyperthermia cancer treatment systems, which have been in use for
several years in the United States, Europe and Asia, are used to treat
certain tumors with heat (hyperthermia) while increasing the
effectiveness of other therapies such as radiation therapy. BSD’s
microwave ablation system has been developed as a stand-alone therapy to
ablate and destroy soft tissue. The Company has developed extensive
intellectual property, multiple products in the market and well
established distribution in the United States, Europe and Asia. Certain
of the Company’s products have received regulatory approvals in the
United States, Europe and China. For further information visit BSD
Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts
are forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
subject to risks and uncertainties detailed in the Company's filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date on which such statements are made,
and the Company undertakes no obligation to update such statements to
reflect events or circumstances arising after such date.